Kael-GemVax Co., Ltd.   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Bundang-gu Korea, Republic of (2001)

Organization Overview

First Clinical Trial
2007
NCT00514072
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

GemVax & Kael

Active Ingredients

Drugs in Phase 3 Trials (2)

gv 1001 (7 trials)

sodium chloride (1 trial)

Drugs in Phase 2 Trials (2)

Key: Kael-GemVax Co., Ltd. (1) Acquired (1)

105ad7 (1 trial)

ony-p1 (1 trial)

Drugs in Phase 1 Trials (1)

ltx-315 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alzheimer Disease (Phase 2)

Carcinoma (Phase 1)

Carcinoma, Non-Small-Cell Lung (Phase 3)

Hyperplasia (Phase 2)

Lung Neoplasms (Phase 3)

Prostatic Hyperplasia (Phase 2)

Prostatic Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 10
  • # of Trial APIs: 5